Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Intraoperative Electron-Beam Radiation Therapy Employs Singe-Dose Technique

By MedImaging staff writers
Posted on 08 Apr 2008
Clinicians at a Japanese hospital are now using intraoperative electron-beam radiation therapy (IOERT) to treat breast cancer patients. More...
The technique allows clinicians to employ the groundbreaking single-dose technique, a treatment that offers considerable physiologic and psychologic benefits to breast cancer patients.

Nagoya University Hospital (Nagoya, Japan) acquired a new device to implement the technology, called the Mobetron, IntraOp Medical Corp's (Sunnyvale, CA, USA) mobile, self-shielding linear accelerator, in October 2006. Nagoya University has had a long history of using IOERT through patient transportation, particularly for the treatment of pancreatic cancer. They are the first hospital in Japan to provide IOERT in a standard operating room. Led by chairman and professor of surgery, Dr. Akimasa Nakao, Nagoya University Hospital doctors have not only continued to use the Mobetron to treat pancreatic cancer, but they are also pioneering the use of IOERT for their breast cancer patients.

The European Institute of Oncology (Milan, Italy) has been a vocal proponent of IOERT for many years. Renowned breast surgeon Dr. Umberto Veronesi, director of the European Institute of Oncology, developed what is known as the single-dose approach for treating breast cancer. Inspired by Dr. Veronesi's record of positive outcomes, Nagoya University Hospital adopted his single-dose technique. Since December 2007, Nagoya University Hospital has been using the Mobetron to administer IOERT to breast cancer treatments.

The term "single-dose” refers to IOERT's ability to eliminate the need for post-surgery radiation therapy. The Mobetron allows Nagoya University Hospital doctors to deliver a single dose of radiation to patients during their cancer surgery. By delivering radiation at the time that the cancerous tissue is excised, the Mobetron administers in one treatment the equivalent of six weeks of postoperative radiation therapy.

The benefits of using the Mobetron to deliver single-dose radiation therapy are numerous. When the Mobetron delivers single-dose IOERT, it allows radiation and surgical oncologists to visually see the exact area they need to radiate and immediately deliver high doses directly to the affected tissue when any residual tumor cells will be most vulnerable. It is more convenient for the patient since all of the radiation that is needed to control the disease is given at the same time as surgery. Single-dose IOERT also results in substantially less dose to the healthy tissues, and there is complete sparing of radiation to the skin, which should lead to better cosmetic results.

In addition to maximizing positive outcomes, using the Mobetron to deliver single-dose radiation therapy greatly reduces the overall treatment time for the patient, resulting in a faster recovery and return to daily life. It also increases the chances for oncoplastic reconstruction at the time of the lumpectomy, making breast reconstruction a real alternative to mastectomy for many breast cancer patients.

"The doctors at the Nagoya University Hospital are delighted to be able to offer single-dose IOERT to their patients,” said Jay Bhatt, senior advisor to IntraOp Medical Corporation. Nagoya University has long been a leader in providing innovative approaches to cancer treatment. With the Mobetron and single-dose IOERT, they are able to continue this tradition. I am convinced that their approach will result in breast preservation for their patients with more convenience at less cost.”

IntraOp Medical provides innovative technology systems for the treatment and eradication of cancer. The company's flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron-radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe, and Asia use the Mobetron as a vital part of their comprehensive cancer program.


Related Links:
Nagoya University Hospital
IntraOp Medical

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.